PAREXEL Opens Two New Locations in China

PAREXEL International Corp. has opened offices in Chengdu and Guangzhou, China to support a broad range of clinical development and regulatory consulting services throughout the Asia/Pacific region. These locations further expand the company’s presence in China, which includes offices in Beijing and Shanghai as well as Kowloon, Hong Kong.

“China, which is one of the fastest growing pharmaceutical markets in the world, is forecasted to become the fifth largest market this year, and reach approximately $47 billion in size by 2013,” said Josef von Rickenbach, chairman and chief executive officer of PAREXEL. “We believe that China is attractive for a wide range of clinical development activities due to its large patient population, cost effective environment, and expanding medical infrastructure. We are working with clients to reduce their development costs, accelerate patient recruitment, and decrease time to market by incorporating China in global development planning, thereby bringing important new safe and effective treatments to patients in China and around the world sooner.”